

# Ventripoint Announces Director Resignation

TORONTO, ON, CA, July 22, 2024 /EINPresswire.com/ -- Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV: VPT; OTC: VPTDF) announces that Robert Hodgkinson has resigned as a director of the Company effective July 22, 2024.



Robert has been an amazing Director for the last 5 years. His enthusiasm for the Company has known no bounds. Nevertheless, it is the hallmark of good governance to have board renewal."

*Dr. George Adams*

"Robert has been an amazing Director for the last 5 years. His enthusiasm for the Company has known no bounds. Nevertheless, it is the hallmark of good governance to have board renewal and so the Company will be appointing a new Director in due course"; stated Dr. George Adams, Executive Chairman of Ventripoint.

Mr. Hodgkinson will continue to advise the Company as he has joined the Board of Business Advisors, which is chaired by Samuel Schwartz.

The Company wishes to thank Robert Hodgkinson for his valuable contributions to the Company and wishes him success in his future endeavors.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams  
gadams@ventripoint.com  
519-803-6937

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

George Adams  
Ventripoint Diagnostics  
+1 5198036937  
Gadams@ventripoint.com

---

This press release can be viewed online at: <https://www.einpresswire.com/article/729568013>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.